Skip Navigation

Annals of Oncology 2005 16(1):158-161; doi:10.1093/annonc/mdi016
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smyth, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smyth, J. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Original article

Phase II study of E7070 in patients with metastatic melanoma

J. F. Smyth1,*, S. Aamdal2, A. Awada3, C. Dittrich4, F. Caponigro5, P. Schöffski6, M. Gore7, T. Lesimple8, N. Djurasinovic9, B. Baron9, M. Ravic10, P. Fumoleau11 and C. J. A. Punt12 On behalf of the EORTC New Drug Development and Melanoma Groups

1 University of Edinburgh, Cancer Research Centre, Western General Hospital, Edinburgh, UK; 2 The Norwegian Radium Hospital, 0310 Oslo 3, Norway; 3 Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium; 4 LBI Applied Cancer Research, Kaiser Franz Josef Spital, Vienna, Austria; 5 Div. Oncologia Medica A, Instituto Nazionale Per lo Studio e la Cura dei Tumori, Italy; 6 Medizinische Hochschule Hannover, Abt. Haematologie und Onkologie, Hannover, Germany; 7 Royal Marsden Hospital, London, UK; 8 Centre Eugene Marquis, Renes, France; 9 EORTC, Avenue Mounier 83, Brussels, Belgium; 10 Centre Rene Gauducheau, Nantes, St-Herblain, Cedex, France; 11 Centre Rene Gauducheau, Boulevard Jacques Monod, F-44805 Nantes, St. Herblain, Cedex, France; 12 University Medical Centre Nijmegen, Department of Medical Oncology, The Netherlands

* Correspondence to: Professor J. Smyth, University of Edinburgh, Cancer Research Centre, Crewe Road South, Edinburgh EH4 2XR, UK. Tel: +44-131-777-3512; Fax: +44-131-777-3520; Email: john.smyth{at}cancer.org.uk

E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m2 of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
J.-P. Liou, K.-S. Hsu, C.-C. Kuo, C.-Y. Chang, and J.-Y. Chang
A Novel Oral Indoline-Sulfonamide Agent, N-[1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-Isonicotinamide (J30), Exhibits Potent Activity against Human Cancer Cells in Vitro and in Vivo through the Disruption of Microtubule
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 398 - 405.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. S. Zandvliet, A. D.R. Huitema, W. Copalu, Y. Yamada, T. Tamura, J. H. Beijnen, and J. H.M. Schellens
CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity
Clin. Cancer Res., May 15, 2007; 13(10): 2970 - 2976.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. S. Zandvliet, W. Copalu, J. H. M. Schellens, J. H. Beijnen, and A. D. R. Huitema
SATURABLE BINDING OF INDISULAM TO PLASMA PROTEINS AND DISTRIBUTION TO HUMAN ERYTHROCYTES
Drug Metab. Dispos., June 1, 2006; 34(6): 1041 - 1046.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.